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Cervical cancer incidence and mortality statistics in Hong Kong during 1972–2001 were examined to estimate the potential number
of cancer cases that can be averted and years of life saved after the launch of an organised, population-based cytologic screening recall
programme in 2004 with projections to 2016. Incidence rates under the status quo of opportunistic screening were projected by an
age–period–cohort model, using maximum likelihood and Bayesian methods. Modelled rates were translated into numbers of
cancer cases and deaths using mid-year population figures and age–period-specific mortality to incidence ratios. We applied
International Agency for Research on Cancer risk reduction estimates for different screening strategies to these base case figures to
estimate the number of incident cancers potentially averted and years of life saved attributable to organised screening incremental to
the current status quo. The estimated numbers of cases projected to be preventable by the maximum likelihood (Bayesian) approach
from 2002 to 2016 were 4226 (4176), 3778 (3728) and 2334 (2287) with organised screening every 1, 3 and 5 years, compared to
haphazard screening currently. Correspondingly, 33000 (32800), 29500 (29300) and 18200 (17900) years of life could potentially
be saved.
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Although the efficacy of cytologic screening had never been
formally tested in randomised controlled trials, there is wide
consensus based on historical data and observational epidemio-
logy that screening leads to significant reductions in both invasive
cancer incidence and mortality (Miller et al, 1976; La Vecchia et al,
1984; Laara et al, 1987; Eddy, 1990; Herrero et al, 1992; Quinn et al,
1999; Peto et al, 2004). Hong Kong first implemented population-
based screening in March 2004 when the government launched its
organised recall programme despite an appreciable cervical cancer
burden (Leung et al, 2005), the availability of financial resources
(annual GDP per capita in 2003¼$22991) and an otherwise
adequate public health infrastructure to sustain such a programme
(Department of Health, 2003). Opportunistic screening had been
increasingly available since the late 1970s and early 1980s. By 2003,
42–60% (depending on the degree of potential under-reporting) of
women aged 21 years or over had been screened at least once
within the last 5 years (Leung et al, 2005).
To examine and quantify the potential public health impact of
this new preventive programme relative to the status quo of
haphazard screening, we adopted the age–period–cohort (APC)
approach, which has been used extensively to predict future
incidence and mortality trends under different public health
intervention scenarios (Osmond, 1985; Dyba and Hakulinen, 2000;
Møller et al, 2003; Quinn et al, 2003). Our primary objective was
to project the number of incident cancers potentially averted
and years of life saved (YLS) attributable to the new organised
screening programme through 2016, by modelling historical
incidence and mortality data from 1972 to 2001 using maximum
likelihood and Bayesian methods.
MATERIALS AND METHODS
Sources of data
Data on cervical cancer incidence and mortality from January 1972
to December 2001 were based on records of the Hong Kong Cancer
Registry. A total of 15140 incident cases (out of a total of 15238
incident cases where the age at diagnosis was unknown in 98 cases)
and 4230 deaths of invasive cervical cancer were included in the
present analysis. Statistics on actual and estimated (beyond 2004)
mid-year population figures were obtained from the Census and
Statistics Department.
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5-year periods and 5-year age groups from 25–29 to 80–84 years,
to give synthetic birth cohorts centred at 5-year intervals since
1892. Age groups below 25 and above 85 years were omitted
because of small numbers.
Age–period–cohort projection of status quo to 2016
Maximum likelihood approach We modified a previously deve-
loped APC model (Leung et al, 2005) and fitted the data by Poisson
regression to compute 15-year projections of incidence rates to the
period 2012–16. Let cij be the observed cases for age group i in
time period j. We assumed that it follows a Poisson distribution
with mean mij, that is, cijBPoisson(mij), and we modelled the
mean as
logðmijÞ¼logðnijÞþai þ bj þ gk þ eij
where ai is the age effect (i¼1, y, I), bj is the period effect (j¼1,
y, J), gk is the cohort effect (k¼1, y, K where k¼Iþj i and
K¼IþJ 1), nij denotes the total number of person-years for age
group i in time period j and eij is the random error term.
We applied linear extrapolation of the six observed periods and
the six most recent birth cohorts based on data from 1972 to 2001
(Osmond, 1985; Negri et al, 1990; Bray, 2002). This set of projected
rates would reflect a continuation of the status quo of opportu-
nistic screening in Hong Kong through 2016 (base case). The
autoregressive nature of our method assumes that current trends
will continue in the future. However, this assumption may not
hold if, say, the future rate of increase in screening uptake is higher
(e.g. as a result of introduction of organised programme) or lower
(e.g. as a result of saturation effect). Therefore, to quantify the
sensitivity of our projection estimates about the continuation of
current trends, we varied future period and cohort effects from  5
to þ5% per 5-year time period over the base case period and
cohort effects, following Osmond (1985). All computations were
performed using SAS version 8.02.
Bayesian approach For comparison purposes, we applied the
Bayesian framework to the APC modelling. A second-order
autoregressive model was specified to smooth the effects of age,
period and cohort, thus guarding against excessive deviation of the
parameter estimates from those in adjacent time bands. The degree
of smoothing was learned from the data on each time scale. The
expected value for each effect was then based on an extrapolation
from its two immediate predecessors. For the age effects ai:
a1   Normal 0; 1000000
1
ta

;
a2   Normal 0; 1000000
1
ta

;
aija1;...;ai 1   Normal 2ai 1   ai 2;
1
ta

for 2oipI
where the hyperparameter ta was a precision parameter determi-
ning the smoothness of the age effect and was given a highly
noninformative prior, namely, taBGamma(0.001, 0.001). The
same type of prior was used for the period and cohort parameters
bj and gk with precision parameters ta and tg, respectively (Breslow
and Clayton, 1993; Bashir and Esteve, 2001; Bray et al, 2001, 2002).
Estimated future rates were computed by combining the estimates
of the age, period and cohort effects obtained. Parameter estimates
and 90% credible intervals were obtained by Markov Chain Monte
Carlo (MCMC) methods. The simulations were run for 12000
iterations with the first 2000 iterations used as burn-in to minimise
the effect of initial values. As successively sampled values were
dependent, samples at suitable spacings of 10 were picked off to
mimic a random drawing of 1000 samples from the posterior. As
with the maximum likelihood APC model, this set of Bayesian
projected rates reflected an extension of the current situation of
opportunistic screening continued to 2016. We also varied the
future period and cohort effects from  5t oþ5% per 5-year time
period as we did for the maximum likelihood estimates. This
model was implemented using BUGS (http://www.mrc-bsu.cam.ac.
uk/bugs/welcome.shtml).
Estimation of potential cases averted and years of life
saved from new organised screening programme
We applied the projected future incidence rates, derived using
maximum likelihood and Bayesian techniques as described above,
to provisional figures of the mid-year female population for the
respective years to calculate the expected number of new cancer
cases through 2016. Population mortality rates were combined
with incidence rates to derive age–period-specific mortality to
incidence (M/I) ratios using observed data from 1972–76 to 1996–
2001 (Taylor et al, 2001). Assuming no change in cancer-specific
survival from potentially improved management of the disease
over the projected time horizon, thereby isolating the effect of
screening on incidence reduction, we applied a constant set of
age–period-specific M/I ratios that were based on the two most
recent observed periods and smoothed using moving averages. The
numbers of cancer-specific deaths to 2016 under the status quo
scenario of opportunistic screening were then calculated from the
numbers of new cancer cases and the application of M/I ratios to
incidence rates in the projection period.
To assess the impact of the new organised screening pro-
gramme, we computed the number of cancer cases under different
screening frequencies by applying the risk reduction estimates as
per the International Agency for Research on Cancer (IARC). The
IARC study, which comprised large screening programmes in eight
European and North American centres for over 20 years (IARC
Working Group, 1986), estimated that the percentage reductions in
the cumulative incidence of cervical cancer in women aged 35–64
years were 91.6, 83.9, 54.0 with every 1-, 3- or 5-year organised
screening, respectively, compared to opportunistic screening. We
derived these figures by calibrating the original IARC estimates,
which were based on the comparator scenario of no screening, to
Hong Kong’s status quo of opportunistic screening. Specifically, we
calculated the expected incidence reduction according to the
opportunistic screening pattern as described below, which yielded
a 22.4% lower incidence compared with no screening. We then
used this as the new baseline to which organised screening patterns
were compared.
Based on the representative 2003 Population Health Survey
(University of Hong Kong, 2005) and a subsequent published
report in interpreting the data (Leung et al, 2005), the pattern of
opportunistic screening in local women was estimated as follows:
 40.7% had never been screened, 15.4% had at least one screen by
age 30 years, 19.6% had at least one screen by age 50 years, 0.1%
were screened regularly every 5 years, 0.5% every 4 years, 3.3%
every 3 years, 4.9% every 2 years and 15.4% annually.
Projected incident case numbers obtained from the APC
modelling were adjusted downwards based on these cancer
incidence reduction figures, beginning from the period 2007–11,
assuming that all Hong Kong women would derive a similar level
of benefit from screening compared to populations in the IARC
study and irrespective of age and other characteristics. We
assumed that the full benefit of the organised screening
programme would only begin from 2007. Estimates for the first
projected period of 2002–06 were obtained by backward project-
ing the 2007 to 2016 figures, assuming a constant decrease in
incidence over the six observed periods. The numbers of cancer-
related deaths were then scaled pro rata according to the
procedure using age–period-specific M/I ratios as specified above.
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the life expectancy at the mean age of death within each group
based on the Hong Kong Life Table (Hong Kong Census and
Statistics Department, 2004) to calculate the number of years of life
lost (YLL) as a result of cervical cancer (Murray and Lopez, 1996).
The marginal difference in YLL between the various screening
scenarios yielded additional YLS attributable to each strategy
benchmarked against the comparator of opportunistic screening.
RESULTS
Goodness-of-fit of maximum likelihood and Bayesian APC
models
Table 1 shows the change in deviance, a measure of goodness-of-
fit, in the sequential building of the maximum likelihood APC
models. Both the age–period (AP) and age–cohort (AC) models
significantly improved the fit over the age only and age–drift
models. The full three-factor model was in turn significantly better
than the two-factor AP (Po0.001) and AC (Po0.001) models by
the F-test (McCullagh and Nelder, 1983), and was therefore
adopted to project future incidence rates by linear extrapolation of
both the period and cohort effects (Osmond, 1985).
The Bayesian APC model also achieved a good fit as indicated
by convergence diagnostics and autocorrelation statistics. Figure A
of the appendix (online) presents convergence diagnostic plots on
selected age, period and cohort parameters from the Bayesian
model. These particular parameters were chosen for illustrative
purposes, as they captured the largest number of cancer cases in
the 50–54 years age group, the birth cohort with central year of
birth in 1942 and 2002–06 was the first projected period. (A full set
of convergence diagnostic plots is available from the authors on
request.) The time-series plots of the MCMC iterations demon-
strate convergence of the Markov chains. Figure B of the appendix
(online) shows autocorrelation plots up to lag 50 for selected
parameters, chosen to represent different age groups (young,
middle and old), years at diagnosis and birth cohorts equally
spaced over the time horizon of the study period. Independence
between samples is confirmed, as the autocorrelations are near
zero for all time-lag separations.
Figure 1 shows observed compared to maximum likelihood and
Bayesian posterior estimates of the fitted rates (1972–76 through
1997–2001) and empirical projections (2002–06 through 2012–
16) of incidence by alternate 5-year age groups in different panels.
Visual inspection confirms that both model fits were generally
good. The graphs suggest an overall decreasing trend, which was
projected to continue in future periods.
Incidence and mortality projections
Figure 2 illustrates the number of fitted and projected cervical
cancer cases and deaths from the maximum likelihood and
Bayesian models under the base case scenario of opportunistic
screening. The maximum likelihood model predicted a net of 51
more cervical cancer incident cases and 91 more death cases than
the Bayesian methodology over the 15 years from 2002 to 2016.
The maximum likelihood and Bayesian estimates were well within
the 90% credible intervals and 95% confidence limits of each other,
respectively (data not shown).
Figure 3 shows the cumulative number of cervical cancer cases
and deaths under the different screening policies. By the maximum
likelihood model, 15-year projections to 2016 estimated that if all
women were screened every 1, 3 and 5 years compared to the status
quo of opportunistic screening, the incremental cumulative
number of cases prevented (YLS) from 2002 to 2016 inclusive
would be 4226 (33000), 3778 (29500) and 2334 (18200),
representing 70, 62 and 38% reductions, respectively. These
cumulative YLS estimates correspond to those presented in
Table 2, assuming 100% coverage. Table 2 also presents results
under different screening coverage/uptake assumptions, namely 75
and 50%. In the sensitivity analysis where we varied future period
and cohort effects by 75% over the base case, the ranges (in
parentheses) for the point estimates in Table 2 show that in the
extreme cases where we assumed a  5% (þ5%) change in both
period and cohort effects in the same direction, the projected
number of deaths would be adjusted by  17.2% (þ25.0%).
Table A of the appendix (online) presents the corresponding
percentage change over the base case estimates for other scenarios.
The graphs for the Bayesian model are almost identical to the
maximum likelihood model and can be found in Figure C of the
appendix (online) and the numerical estimates are included in
Table 2.
DISCUSSION
Analysis of secular trends in cancer epidemiology is important to
the assessment of public health control policy. Cervical cancer
mortality projections based on APC trends presented herewith
suggest that the introduction of effective population screening
could potentially prevent a continuing epidemic that would have
culminated in about 4000 cancer deaths and 30000 years of life
by 2016, incremental to the current status quo of haphazard
screening.
The direction and magnitude of our models and estimates are
generally in line with other similar projection exercises reported in
the literature. For instance, in England and Wales, Peto et al (2004)
estimated that the National Health Service Cervical Screening
Program, built on a history of opportunistic screening and which
increased the smear coverage rate to 80%, was responsible for
reducing cervical cancer incidence by 42% from the launch of the
programme in 1988 up to 2000. In comparison, our model
predicted that with organised screening aiming at 75% coverage,
screening every 3 and 5 years would result in a comparable cancer
incidence reduction of 44 and 39%, respectively, over the
subsequent 15 years.
The present estimates are also comparable when benchmarked
against historical observations. For example, in Sweden, organised
screening was implemented in the mid-1960s and since then, there
had been a steady decline in cervical cancer incidence of about
60% during 1959–93 (Dillner, 2000). Similarly, Finland’s incidence
dropped by 70–80% over the same period (Anttila and Nieminen,
2000). Based partly on Europe’s experience, IARC (2005) estimated
in a recent report that incidence reduction attributable to high-
quality organised programme with virtually complete population
coverage can be as high as 80%. Our model, assuming 100%
coverage, predicted that new cancer cases could potentially
decrease by 70% with screening every year and by 60% with
screening every 3 years compared to the status quo of
opportunistic testing.
In this projection exercise, we assumed that all women would
derive the same level of benefit from cytologic screening
irrespective of age and other risk characteristics in adopting the
Table 1 Summary statistics comparing goodness-of-fit for different
maximum likelihood models
Model Degrees of freedom Deviance P-value
Age 60 1805.2
Age–drift 59 270.9
Age–period 55 214.6 o0.001
Age–cohort 44 111.0 o0.001
Age–period–cohort 40 68.5
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were predicated on the local screening programme achieving the
same level of sustained effectiveness as that demonstrated in
the IARC study starting from 2007. Nevertheless, we varied the
population coverage proportions to demonstrate how the
projected figures would change depending on screening uptake
as per Table 2.
We did not model mortality trends directly because survival
statistics are influenced by changes in treatment protocols and care
patterns in addition to screening. Bonneux (2004) highlighted two
common pitfalls of mortality models concerning the high level of
uncertainty in estimating deaths averted from screening alone and
a tacit assumption that cervical cancer risk in the future is constant
by disregarding secular trends of incidence. In contrast, by
focusing on incidence reduction through screening and extra-
polating cancer deaths averted as a function of changes in
incidence rates only, we were able to exclude the confounding
effects of improved treatment and changing care practice over
time. However, there is an important potential caveat associated
with this approach concerning the underestimation of the benefit
of screening. Specifically, screening can reduce cervical cancer
mortality in two ways: (1) incidence reduction through early
detection and treatment of precancerous lesions (CIN 1–3) before
progression to invasive disease and (2) stage shift at the time of
diagnosis towards earlier stages of invasive cancer thereby
potentially improving survival. It is unclear how much of the
overall benefit of cytologic screening, in terms of lowered
mortality, can be attributed to each of these two components.
Nevertheless, current consensus suggests that the former effect
predominates in terms of number of deaths averted or YLS,
although the verdict remains to be confirmed for outcome indices
taking into account quality of life, for example, quality-adjusted
life-years (QALYs) saved. Implicit in our M/I ratio method, we
disregarded the latter effect owing to a lack of stage-specific
incidence data in the local disease registry, and that all invasive
tumours have been recorded as cancer cases irrespective of stage.
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Figure 1 Observed compared to maximum likelihood (solid lines) and Bayesian posterior estimates (shaded lines) of fitted rates (1972–76 through
1997–2001) and empirical projections (2002–06 through 2012–16) of incidence by alternate 5-year age groups.
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tude of mortality reduction as a result of screening.
From the methodological viewpoint, we built on previous work
(Dyba and Hakulinen, 2000; Bashir and Esteve, 2001; Møller et al,
2003) on comparing different maximum likelihood APC modelling
techniques by extending the methodology to a Bayesian approach.
We adopted the second-order autoregressive Poisson model,
recognised as likely the most reliable maximum likelihood
technique as per Bashir and Esteve (2001) and Dyba and
Hakulinen (2000), as the maximum likelihood comparator to the
Bayesian method and found that both analytic approaches yielded
very similar estimates, thus lending added credibility to the
projected estimates.
In terms of policy implementation, we note a practical caveat
concerning the predictive relevance of our findings vis-a `-vis the
organised screening programme launched in Hong Kong in 2004
(http://www.cervicalscreening.gov.hk/). Currently, as a result of
resource constraints, this government-operated programme
mainly provides a prospective record and recall function for those
who have ever been screened. The programme encourages women
to undergo regular cytologic examination through social market-
ing campaigns for the general public and via primary care and
women’s health providers to individuals on an opportunistic basis.
For those women who decide to get screened, they can seek to be
tested at public or private care providers on a full fee-for-service
basis using either traditional pap smear or liquid-based method
with/without human papilloma virus (HPV) testing. These
providers are then encouraged to enter the screened woman’s
details into a centralised database for subsequent automatic recall
(every 3 years) and archiving of test results. Therefore, without
explicitly anchoring the programme with proactive, personalised
invitation to be screened (initial ‘call’ function) and direct
provision of pap testing at dedicated facilities for a reasonable
fee (as opposed to full market rates), it is a suboptimal
arrangement by Hakama and et al’s (1985) definition of an ideal
programme. Nevertheless, referral for colpolscopy and subsequent
management in the case of invasive disease are available in both
the public and private sectors, where the former essentially
provides universal access to all services with very minimal co-
payments (amounting to an all-inclusive per diem charge of less
than d7 or $13) at the point of care. Indeed, the public sector
provides 95% of total bed-days for all in-patient care locally. As at
March 2005 after 12 months in operation, just under 120000
(4.8%) women out of a potentially eligible female population of 2.5
million aged 21–69 years have been registered, even though we
know that between 42 and 60% of local women reported being ever
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Figure 2 Observed and predicted cervical cancer incident cases and deaths from 1972 to 2016 with continuation of the status quo of opportunistic
screening.
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Figure 3 Cumulative incident cases and deaths from 1972 to 2016 under different screening scenarios by the maximum likelihood model.
Table 2 Years of life saved derived from both maximum likelihood and Bayesian models by adopting a population-based cytologic screening call–recall
programme vs the status quo of opportunistic screening
Every 5 years Every 3 years Every 1 year
Maximum likelihood model
100% coverage 18200 (15100, 22700) 29500 (24400, 36800) 33000 (27300, 41200)
75% coverage 10900 (9000, 13600) 18700 (15500, 23400) 20800 (17200, 26000)
50% coverage 3900 (3200, 4900) 8900 (7400, 11200) 10300 (8600, 12900)
Bayesian model
100% coverage 17900 (14900, 22400) 29300 (24200, 36600) 32800 (27200, 41000)
75% coverage 11000 (9100, 13700) 18800 (15600, 23500) 20900 (17300, 26100)
50% coverage 4000 (3300, 5000) 9000 (7500, 11300) 10100 (8400, 12600)
Numbers are rounded to the nearest hundred. Ranges (in parentheses) around the point estimates were calculated by varying the percentage change in future period and cohort
effects per 5-year time period from  5 to 5% over the base case values. A  5% change in both period and cohort effects yielded an overall percentage change of  17.2%, while
a +5% change in both period and cohort effects resulted in an overall percentage change of +25.0% over the 15-year projected period.
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projected benefits of organised screening can be realised, perhaps
with modification and enhancements subsequently to the present
programme arrangements.
Lastly, our models did not take into account scientific advances
in cancer biology and related research. There has been unprece-
dented progress in our understanding of the origin and
pathogenesis of cervical neoplasia in the past decade. With the
prospect of primary prevention of cervical cancer by a prophy-
lactic HPV vaccine and/or secondary/tertiary prevention by a
therapeutic vaccine at the stages of in situ or invasive disease on
the horizon (Rohan et al, 2003), recombinant DNA technologies
may render the prevention and eradication of the vast majority of
cervical cancer cases a real possibility.
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